{"ctNumber":"2024-515184-65-01","ctStatus":"Authorised","decisionDate":"2026-08-26T14:54:42.776","publishDate":"2026-08-27T03:31:27.603099695","ctPublicStatusCode":2,"authorizedApplication":{"authorizedPartI":{"id":141779,"rowSubjectCount":0,"products":[{"id":591391,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"13227183","productPharmForm":"CAPSULE","euMpNumber":"PRD13227183","prodAuthStatus":1,"prodName":"MDMA hydrochloride","pharmForm":"CAPSULE","activeSubstanceName":"MIDOMAFETAMINE HYDROCHLORIDE","euSubstNumber":"SUB127825","nameOrg":"AMSTERDAM UMC","productSubstances":[{"productPk":"13227183","substancePk":"394616","nameOrg":"AMSTERDAM UMC","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"MIDOMAFETAMINE HYDROCHLORIDE","substanceEvCode":"SUB127825","synonyms":["MDMA HYDROCHLORIDE"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"120","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"320","maxTreatmentPeriod":4,"timeUnitCode":"3","evCode":"PRD13227183","devices":[],"characteristics":["2"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"MDMA hydrochloride","jsonActiveSubstanceNames":"midomafetamine hydrochloride","pharmaceuticalFormDisplay":"CAPSULE"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"MDMA-assisted therapy for adolescents with treatment-resistant PTSD","fullTitleTranslations":[{"id":11990118,"uuid":"c64a302c-d09f-4f25-9079-e88216615914","attributeTranslation":"MDMA-ondersteunde therapie voor adolescenten met behandelresistente PTSS","language":37,"languageDescription":"Dutch (Netherlands)"}],"publicTitle":"MDMA-assisted therapy for adolescents with treatment-resistant PTSD","publicTitleTranslations":[{"id":11990127,"uuid":"1b349d11-4795-4cf5-97f6-9f1dfbb4d37a","attributeTranslation":"MDMA-ondersteunde therapie voor adolescenten met behandelresistente PTSS","language":37,"languageDescription":"Dutch (Netherlands)"}],"secondaryIdentifyingNumbers":{"whoUniversalTrialNumber":{"id":575126,"number":"U1111-1335-6444"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"Therapeutic exploratory clinical trial in patients","trialCategoryId":131106},"medicalCondition":{"partIMedicalConditions":[{"id":148574,"medicalCondition":"Post-traumatic stress disorder","medicalConditionTranslations":[{"id":11990101,"uuid":"ba3ba949-4c77-433f-8beb-4774772c3245","attributeTranslation":"Post-traumatische stressstoornis","language":37,"languageDescription":"Dutch (Netherlands)"}],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"4","trialScopeId":431234},{"code":"13","otherDescription":"Feasability","trialScopeId":431235}],"mainObjective":"To assess the feasibility and safety of MDMA-assisted therapy for adolescents (16 through 18 years old) with treatment-resistant PTSD.","mainObjectiveTranslations":[{"id":11990126,"uuid":"535474e4-e65d-465d-bd1d-b5f54b2adc42","attributeTranslation":"Het testen van de haalbaarheid en veiligheid van MDMA-ondersteunde therapie voor adolescenten (leeftijd 16-18) met behandelresistente post-traumatische stressstoornis","language":37,"languageDescription":"Dutch (Netherlands)"}],"secondaryObjectives":[{"id":507332,"number":1,"secondaryObjective":"To assess within-subject change in PTSD symptoms following MDMA-assisted therapy","secondaryObjectiveTranslations":[{"id":11990128,"uuid":"be453eab-25d8-4d0b-81d3-fbb2e53be375","attributeTranslation":"Het vaststellen van verandering van PTSS-symptomen na MDMA-ondersteunde therapie","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":507333,"number":2,"secondaryObjective":"To assess negative effects of treatment","secondaryObjectiveTranslations":[{"id":11990129,"uuid":"4a5615ac-c73d-4086-b881-685b66f7b0f7","attributeTranslation":"Het vaststellen van negatieve effecten van behandeling","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":507334,"number":3,"secondaryObjective":"To assess changes in anxious and depressive symptoms, post-traumatic cognitions, resilience, working alliance, and wellbeing.","secondaryObjectiveTranslations":[{"id":11990130,"uuid":"00efb6c7-070f-4952-b27b-fc0ce34a8c09","attributeTranslation":"Het vaststellen van verandering in symptomen van angst en depressie, post-traumatische cognities, weerbaarheid, therapeutische alliantie, en welzijn","language":37,"languageDescription":"Dutch (Netherlands)"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":965943,"number":1,"principalInclusionCriteria":"Is 16 through 18 years of age.","principalInclusionCriteriaTranslations":[{"id":11990119,"uuid":"985525c8-90ca-436e-98cc-bdbe50b9d02d","attributeTranslation":"Is 16 t/m 18 jaar oud","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":965944,"number":2,"principalInclusionCriteria":"Meets criteria for PTSD according to the CAPS-CA-5.","principalInclusionCriteriaTranslations":[{"id":11990120,"uuid":"e62d62b5-d289-494c-bce8-10f0d68e3981","attributeTranslation":"Voldoet aan de criteria voor PTSS volgens de CAPS-CA-5","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":965945,"number":3,"principalInclusionCriteria":"Has previously followed at least one evidence-based treatment programs without significant symptom reduction.","principalInclusionCriteriaTranslations":[{"id":11990121,"uuid":"a86b6aed-f9e0-4029-a91b-42593c887e11","attributeTranslation":"Heeft eerder ten minste een evidence-based behandeling doorlopen zonder significante vermindering van symptomen.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":965946,"number":4,"principalInclusionCriteria":"Has a social support system, such as parents, foster parents, or mentor, in place that is willing and able to participate.","principalInclusionCriteriaTranslations":[{"id":11990122,"uuid":"2a86290d-aa27-4ea4-8fdf-6c90335727ec","attributeTranslation":"Heeft een sociaal ondersteunings netwerk, zoals ouders, pleegouders, of mentor in plaats dat wil en in staat is bij te dragen.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":965947,"number":5,"principalInclusionCriteria":"Is in adequate safety during the trial (e.g., a stable place to live, no ongoing stalking).","principalInclusionCriteriaTranslations":[{"id":11990123,"uuid":"248caa12-9794-4554-931b-394d58e41b4a","attributeTranslation":"Bevindt zich in voldoende veiligheid tijdens de studie (e.g., een vaste woonplaats, geen huidige stalking)","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":965948,"number":6,"principalInclusionCriteria":"Is willing to establish and commit to a plan for post-treatment care with current referrer.","principalInclusionCriteriaTranslations":[{"id":11990124,"uuid":"3d272941-6963-4949-bb50-bfbe660687e5","attributeTranslation":"Is bereid om een nazorgplan met de huidige verwijzer op te stellen en zich hieraan te committeren","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":965949,"number":7,"principalInclusionCriteria":"Provides written informed consent","principalInclusionCriteriaTranslations":[{"id":11990125,"uuid":"c71b9ada-dcd1-48bc-9c7c-035a151d4a7b","attributeTranslation":"Verstrekt schriftelijke, geïnformeerde toestemming","language":37,"languageDescription":"Dutch (Netherlands)"}]}],"principalExclusionCriteria":[{"id":1648807,"number":1,"principalExclusionCriteria":"Inability to speak and write Dutch.","principalExclusionCriteriaTranslations":[{"id":11990107,"uuid":"bb491b45-c314-436f-b6cd-21355fbda1a7","attributeTranslation":"Onvermogen om Nederlands te spreken en te schrijven","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648808,"number":10,"principalExclusionCriteria":"Known hypersensitivity to MDMA or to any of the excipients of the investigational medicinal product.","principalExclusionCriteriaTranslations":[{"id":11990108,"uuid":"793e47d1-86ed-4f93-a672-34faec202234","attributeTranslation":"Bekende overgevoeligheid voor MDMA of voor een van de hulpstoffen van het onderzoeksproduct","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648809,"number":11,"principalExclusionCriteria":"Recreational MDMA use within 3 months before the first MDMA-assisted session.","principalExclusionCriteriaTranslations":[{"id":11990109,"uuid":"b6c928ff-e953-4b0d-ab57-8ba5ac1e446a","attributeTranslation":"Recreationeel MDMA gebruik binnen drie maanden voor de eerste MDMA-ondersteunde sessie","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648810,"number":2,"principalExclusionCriteria":"Sexually active females who are not practicing an effective means of birth control and pregnant females.","principalExclusionCriteriaTranslations":[{"id":11990110,"uuid":"42a57812-c140-46b4-9ec2-efeea579c05c","attributeTranslation":"Seksueel actieve vrouwen die geen effectieve anticonceptiemethode gebruiken en zwangere vrouwen","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648811,"number":3,"principalExclusionCriteria":"Evidence or history of significant hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder.","principalExclusionCriteriaTranslations":[{"id":11990111,"uuid":"7e0433f1-0208-4920-8a6d-c59f211de97b","attributeTranslation":"Aanwijzingen voor of een voorgeschiedenis van significante hematologische, endocriene, cerebrovasculaire, cardiovasculaire, coronaire, pulmonale, renale, gastro-intestinale, immuunonderdrukkende of neurologische aandoeningen, waaronder epilepsie","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648812,"number":4,"principalExclusionCriteria":"Acute suicidality, psychotic problems, bipolar disorder, or substance use disorder.","principalExclusionCriteriaTranslations":[{"id":11990112,"uuid":"cd072251-ff50-4ee2-b5be-e35b998f618c","attributeTranslation":"Acute suïcidaliteit, psychotische problemen, bipolaire stoornis, of stoornis in het gebruik van middelen","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648813,"number":5,"principalExclusionCriteria":"Any of the following cardiovascular conditions: hypertension, coronary artery disease, pe-ripheral vascular disease, congenital long QT syndrome, cardiac hypertrophy, cardiac ische-mia, congestive heart failure, tachycardia, artificial heart valve, or any other significant car-diovascular condition.","principalExclusionCriteriaTranslations":[{"id":11990113,"uuid":"4dafd4db-a538-4e2a-8be7-78b50b43cf4c","attributeTranslation":"Een van de volgende cardiovasculaire aandoeningen: hypertensie, coronaire hartziekte, perifere vaatziekte, aangeboren lang QT-syndroom, hartvergroting, hartischemie, congestief hartfalen, tachycardie, kunsthartklep of een andere significante cardiovasculaire aandoening.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648814,"number":6,"principalExclusionCriteria":"Estimated or determined intellectual disability (IQ <70).","principalExclusionCriteriaTranslations":[{"id":11990114,"uuid":"e249a855-f29e-4a77-8aa4-2b6270f7e383","attributeTranslation":"Geschatte of vastgestelde verstandelijke beperking (IQ <70)","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648815,"number":7,"principalExclusionCriteria":"Suffering from ongoing trauma by a parent who is part of the adolescent’s current primary-care system.","principalExclusionCriteriaTranslations":[{"id":11990115,"uuid":"b6a44b02-3b4f-4295-8d1d-30e3e329b1a7","attributeTranslation":"Lijdend aan trauma veroorzaakt door een ouder die deel uitmaakt van het huidige zorgsysteem van de adolescent","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648816,"number":8,"principalExclusionCriteria":"Have any current problem which, in the opinion of the investigator or medical staff, might interfere with participation.","principalExclusionCriteriaTranslations":[{"id":11990116,"uuid":"8efee6fc-133b-4f97-9290-39d8624231cb","attributeTranslation":"Heeft momenteel een probleem dat, naar het oordeel van de onderzoeker of het medisch personeel, deelname zou kunnen belemmeren","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1648817,"number":9,"principalExclusionCriteria":"Pregnant or breastfeeding, or a positive urine pregnancy test at screening for participants who are able to become pregnant.","principalExclusionCriteriaTranslations":[{"id":11990117,"uuid":"d1cc7cc9-be9f-449f-998b-5cdeceb7491a","attributeTranslation":"Is zwanger of geeft borstvoeding, of heeft een positieve urine zwangerschapstest tijdens screening voor deelnemers die zwanger kunnen worden.","language":37,"languageDescription":"Dutch (Netherlands)"}]}]},"endPoint":{"primaryEndPoints":[{"id":1129014,"number":1,"endPoint":"The primary feasibility endpoint is treatment completion, defined as the proportion of participants who complete all three MDMA-assisted sessions and the assessment within one week after the final integration session.","isPrimary":true,"endPointTranslations":[{"id":11990102,"uuid":"d49dc805-2697-4f86-960c-568e7f890ecd","attributeTranslation":"Het primaire haalbaarheidseindpunt is de behandelingsvoltooiing, gedefinieerd als het aandeel deelnemers dat alle drie de MDMA-ondersteunde sessies en de beoordeling binnen een week na de laatste integratiesessie voltooit.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1129015,"number":2,"endPoint":"Safety will be assessed by the number of adverse events and serious adverse events, and treatment discontinuations until the end of the study.","isPrimary":true,"endPointTranslations":[{"id":11990103,"uuid":"905e9df0-0281-4e61-b25c-6008ae5dd461","attributeTranslation":"Veiligheid wordt beoordeeld aan de hand van het aantal bijwerkingen en ernstige bijwerkingen, en vroegtijdige stopzettingen van de behandeling tot het einde van de studie.","language":37,"languageDescription":"Dutch (Netherlands)"}]}],"secondaryEndPoints":[{"id":1129016,"number":1,"endPoint":"Change in CAPS-CA-5 total score from baseline to within one week after the final integration session.","isPrimary":false,"endPointTranslations":[{"id":11990104,"uuid":"e3bc1bf1-0d2b-40c4-aee0-7f7cbad4a5e6","attributeTranslation":"Verandering van CAPS-CA-5 totale score van baseline tot binnen een week na de laatste integratie sessie","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1129017,"number":2,"endPoint":"NEQ questionnaire at within one week after the final integration session","isPrimary":false,"endPointTranslations":[{"id":11990105,"uuid":"81321409-f986-4714-944e-aa97ac69f07b","attributeTranslation":"NEQ vragenlijst binnen een week na de laatste integratie sessie","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1129018,"number":3,"endPoint":"Change in PROMIS Anxiety, PROMIS Depression, cPTCI, CYRM-R, WAV-12, Cantril ladder, Resilience Cantril ladder, and EQ-5D from baseline to within one week after the final integration session.","isPrimary":false,"endPointTranslations":[{"id":11990106,"uuid":"686461fb-d152-489a-9a99-a25175a79aa6","attributeTranslation":"Verandering in PROMIS Anxiety, PROMIS Depression, cPTCI, CYRM-R, WAV-12, Cantril ladder, Resilience Cantril ladder, and EQ-5D van baseline tot binnen een week na de laatste integratie sessie","language":37,"languageDescription":"Dutch (Netherlands)"}]}]},"trialDuration":{"estimatedEndDate":"2029-03-31","estimatedRecruitmentStartDate":"2026-10-01"},"sourceOfMonetarySupport":[{"id":104440,"organisationName":"ZonMw"}],"populationOfTrialSubjects":{"ageRanges":[{"id":389646,"ageRangeCategoryCode":"2","ageRangeCategory":"2"}],"ageRangeSecondaryIds":[{"id":389647,"ageRangeCategoryCode":"2","ctAgeRangeCode":"6","ageRangeCategory":"2","ctAgeRange":"6"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"1","planDescription":"After publication of the primary analyses of the data, all deidentified data - as assessed by the privacy officer AUMC - will be made available via FAIR, open-access databases."}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[{"id":37498,"ctNumber":"2024-515184-65-00","sponsorName":"Stichting Amsterdam UMC","fullTitle":"MDMA-assisted therapy for adolescents with treatment-resistant PTSD","sponsorAgreementOption":"NON_APPLICABLE","sponsorAgreementOptionName":"NON_APPLICABLE","parentClinicalTrialId":16103,"hasDocument":false,"associatedCtDocs":[]}],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-08-26","conclusionDate":"2026-08-26","therapeuticAreas":[{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}],"medicalConditions":[{"id":148574,"medicalCondition":"Post-traumatic stress disorder","isConditionRareDisease":false}],"sponsors":[{"id":161587,"primary":true,"publicContacts":[{"id":476992,"type":"Public","functionalName":"Josjan Zijlmans","functionalEmailAddress":"j.zijlmans@amsterdamumc.nl","telephone":"0651006984","organisation":{"id":508442,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Stichting Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":476993,"type":"Scientific","functionalName":"Josjan Zijlmans","functionalEmailAddress":"j.zijlmans@amsterdamumc.nl","telephone":"0651006984","organisation":{"id":508442,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Stichting Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":508442,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Stichting Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"},"addresses":[{"id":476051,"organisation":{"id":508442,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Stichting Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"},"address":{"addressId":510539,"oneLine":"De Boelelaan 1117","addressLine1":"De Boelelaan 1117","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amsterdam","postcode":"1081 HV","country":2029,"countryName":"Netherlands"},"email":"ctis&#64;amsterdamumc.nl","isBusinessKeyValidated":true,"businessKey":"ORG-100008355"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Therapeutic exploratory clinical trial in patients","partOneTherapeuticAreas":[{"id":1233155,"therapeuticArea":{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}}],"productRoleGroupInfos":[{"id":438811,"comments":"MDMA hydrochloride","productRoleCode":"1","productRoleName":"Test","products":[{"id":591391,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"13227183","productPharmForm":"CAPSULE","euMpNumber":"PRD13227183","prodAuthStatus":1,"prodName":"MDMA hydrochloride","pharmForm":"CAPSULE","activeSubstanceName":"MIDOMAFETAMINE HYDROCHLORIDE","euSubstNumber":"SUB127825","nameOrg":"AMSTERDAM UMC","productSubstances":[{"productPk":"13227183","substancePk":"394616","nameOrg":"AMSTERDAM UMC","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"MIDOMAFETAMINE HYDROCHLORIDE","substanceEvCode":"SUB127825","synonyms":["MDMA HYDROCHLORIDE"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"120","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"320","maxTreatmentPeriod":4,"timeUnitCode":"3","evCode":"PRD13227183","devices":[],"characteristics":["2"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"MDMA hydrochloride","jsonActiveSubstanceNames":"midomafetamine hydrochloride","pharmaceuticalFormDisplay":"CAPSULE"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":328964,"mscId":58377,"mscInfo":{"id":58377,"clinicalTrialId":27929,"countryOrganisationId":2029,"reportingStatusCode":"Authorised","fromDate":"2026-08-05","toDate":"2026-08-05","isProposedRms":true,"countryName":"Netherlands","organisationInfo":{},"firstDecisionDate":"2026-08-26","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":461429,"mscId":58377,"trialStatus":"Authorised","trialStatusDate":"2026-08-26T14:54:42.585"},{"id":386556,"mscId":58377,"trialStatus":"Under evaluation","trialStatusDate":"2026-05-18T14:59:12.115"}],"applicationTypeMsc":"1","mscName":"Netherlands","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-18","decision":"authorized_conditions","decisionDate":"2026-08-26"},"decisionDate":"2026-08-26","recruitmentSubjectCount":12,"trialSites":[{"id":2310686,"organisationAddressInfo":{"id":887985,"organisation":{"id":930023,"type":"Patient organisation/association","typeCode":"6","name":"Amsterdam UMC Stichting","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"},"address":{"addressId":991749,"oneLine":"De Boelelaan 1117","addressLine1":"De Boelelaan 1117","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amsterdam","postcode":"1081 HV","country":2029,"countryName":"Netherlands"},"phone":"0205663383","email":"ctis@amsterdamumc.nl","isBusinessKeyValidated":true,"businessKey":"ORG-100008355"},"personInfo":{"id":2561502,"firstName":"Ramon","lastName":"Lindauer","telephone":"0205663383","email":"ctis@amsterdamumc.nl"},"departmentName":"Child and Adolescent Psychiatry"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":78840,"type":"INITIAL","status":"Authorised","ctNumber":"2024-515184-65-01","trialStatus":"Authorised","submissionDate":"2026-05-18","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-08-26"},"partIIInfo":[{"id":328964,"mscId":58377,"mscInfo":{"id":58377,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-18","decision":"authorized_conditions","decisionDate":"2026-08-26","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2026-08-26"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-08-26","ctMSCsByApplication":[{"id":58377,"mscName":"Netherlands","reportingStatusCode":"Authorised"}],"businessKey":"IN-1","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":139391,"applicationId":78840,"mscId":58377,"mscName":"Netherlands","decisionDate":"2026-08-26T14:54:42.776","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":328964,"part1Id":141779,"applicationType":"INITIAL","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Netherlands","mscId":58377,"firstDecisionDate":"2026-08-26T14:54:42.776","lastDecisionDate":"2026-08-26T14:54:42.776","mscPublicStatusCode":2}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":58377,"mscName":"Netherlands","events":[]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_Protocol 2024-515184-65-01","uuid":"7a426771-ef8b-4b9d-853e-906fa7850400","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"4","systemVersion":"4"},{"title":"D4_Patient-facing documents Cantril Ladder","uuid":"78337948-2d31-4faf-aab8-3681c3c08fb9","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents cPTCI","uuid":"5ed3d669-a3fc-4d76-85c4-34b3b9541a14","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents CYRM-R","uuid":"0166cfe0-a59e-4c13-83e7-8a3b57d7f2c3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents CATS","uuid":"077dc48d-0973-4e17-85a8-e35cdcf91429","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents TIPI","uuid":"846d2d77-44e4-4e41-a0df-d3be1801d683","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents PROMIS Anxiety","uuid":"67ce25cf-55cd-45cb-981f-cb29b42f22ab","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents NEQ","uuid":"ec8ffd93-1e9f-4b2f-8697-860001eac90b","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents PROMIS Depressive Symptoms","uuid":"3dc4cb90-3212-4f3d-8313-b55fd36f611c","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents Resilience Cantril ladder","uuid":"ed543ad6-2104-4307-aae9-870975140297","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents EQ-5D","uuid":"4326f8ed-3254-4cb9-b4e7-69c3e63bedcf","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents WAV-12","uuid":"daa1c0f7-0535-4d96-bd2b-a35e790f6b3e","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient-facing documents CAPS-CA-5","uuid":"548b271a-b0ac-4c43-8da3-0c48fe250a4a","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Protocol synopsis NL 2024-515184-65-01","uuid":"7349b91c-d020-453c-9a60-87c3251aa3e0","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":141779,"manualVersion":"2","systemVersion":"2"},{"title":"K1_Recruitment arrangements","uuid":"aae9094b-4340-43df-884d-13b36ded5e0c","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":328964,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF 16-18 yr","uuid":"ed12d694-4714-408c-87ad-eafb6f2f17cc","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":328964,"manualVersion":"3","systemVersion":"3"},{"title":"L2_Other_subject_information_material_leaflet","uuid":"05210d07-f013-4a55-81b0-05fc46a09561","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":328964,"manualVersion":"1","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}